Sorin Group S.p.A. Cardiac Rhythm Management Announces CE Mark and First Implant of a New-Generation CRT-D Device Designed to Provide Hemodynamic Management of Heart Failure

PARIS--(BUSINESS WIRE)--Sorin Group (MIL:SRN) Cardiac Rhythm Management announced today the first implant in a clinical trial of its new-generation PARADYM™ 8770 sonR™1 cardiac resynchronization therapy defibrillator (CRT-D). This system contains a unique technology named sonR™ designed to adjust CRT delivery based on hemodynamic response as opposed to conventional CRT-D devices, that monitor the electrical activity of the heart. PARADYM™ sonR™ is the first device delivering continuous management of resynchronization therapy during patients’ everyday life.